Full Press Release Details
Inspira Announces Plans to Report the Primary Results for
a Core Blood Oxygenation Technology Within Days
Ra'anana, Israel, March 04, 2024 (GLOBE
NEWSWIRE) -- Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) (the "Company" or "Inspira"),
a breakthrough medical technology company, announced today that the Company's President, and co-founder, Mr. Joe Hayon, presented
key highlights included in the Company's Investor Presentation and announced the Company's next major milestone of a core
blood oxygenation technology of the INSPIRA ART (Gen 2). The INSPIRA ART (Gen 2) is designed to utilize adaptive oxygenation technology,
leveraging the proprietary HYLA blood Sensor and VORTX Orbiting Blood Oxygenation, to delivery oxygen straight into the
blood. The proprietary core technology has undergone a series of testing in a variety of settings, with the results being collected and
analyzed. The results refer to the INSPIRA ART (Gen 2), with the new core technology potentially being suitable for replacing current
solutions in medical markets dominated by leading medical device companies. The Company plans to announce the primary results around
the core blood oxygenation technology of the INSPIRA ART (Gen 2) within days.
Mr. Hayon shared "We have an appetite to revolutionize the huge
life-support mechanical ventilation market. In addition, it's important to emphasize that we believe INSPIRA ART100 (Gen 1) itself
addresses $1B market." Key highlights from the conference call included:
Mr. Hayon shared a heartfelt personal story and the profound impact
of Inspira beyond technological innovation. He recounted his father's prolonged reliance on mechanical ventilation, painting a vivid picture
of the challenges and complications associated with traditional ventilation methods. Through conversations with critical care physicians,
the necessity for Inspira's technology became clear - a sentiment echoed by medical professionals eager to integrate INSPIRA ART
into clinical practice.
Emphasizing the Company's core mission, Mr. Hayon continued to share
how Inspira is focused on delivering oxygen straight into the blood. The Company is advancing two generations of blood oxygenation solutions.
INSPIRA ART100 (Gen 1), designed to perform blood oxygenation as a cardio-pulmonary bypass device, is anticipated to be cleared by the
FDA in the first half of 2024. With the planned FDA submission and clearance of the HYLA, the INSPIRA ART100 is then intended to be integrated
with blood monitoring technologies from the HYLA. In parallel, the Company is rapidly developing the INSPIRA ART (Gen 2), designed to
perform adaptive blood oxygenation, embedded with the HYLA advanced continuous blood monitoring, to provide real-time detection of changes
and provide decision-making assistance data and the VORTX orbiting blood oxygenation delivery system.
We believe that since the blood holds so many secrets about patient
condition and response to treatment, the collection, aggregation and analysis of data by the INSPIRA ART will potentially open a huge
market opportunity for the Company, as we aim to revolutionize the treatment of patients while they are awake and without the need for
mechanical ventilation. The forthcoming expected FDA clearance of the INSPIRA ART100 will mark a pivotal achievement, which we believe
will reinforce Inspira's position as a disruptive force in the medical landscape.
Inspira Technologies OXY B.H.N. Ltd.
Inspira Technologies is an innovative medical technology company
in the respiratory treatment arena. The Company has developed a breakthrough Augmented Respiration Technology (INSPIRA ART), designed
to rebalance patient oxygen saturation levels. This technology potentially allows patients to remain awake during treatment while reducing
the need for highly invasive, risky, and costly mechanical ventilation systems that require intubation and medically induced coma. The
Company's products have not yet been tested or used in humans and has not been approved by any regulatory entity.
For more information, please visit our corporate website: https://inspira-technologies.com
Forward-Looking Statement Disclaimer
This press release contains express or implied forward-looking statements
pursuant to U.S. Federal securities laws. These forward-looking statements and their implications are based on the current expectations
of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ
materially from those described in the forward-looking statements. For example, the Company is using forward-looking statements when it
discusses the potential benefits of the Company's products and potential products, the potential addressable market for its products,
that it intends to announce the primary results for its core blood oxygenation technology within days, the expected timing of FDA approval
and the intended future submission of products for FDA approval, the belief that the INSPIRA ART will potentially open a huge market opportunity
and that the expected FDA clearance of the INSPIRA ART100 will mark a pivotal achievement, which it believes will reinforce its position
as a disruptive force in the medical landscape. These forward-looking statements and their implications are based solely on the current
expectations of the Company's management and are subject to a number of factors and uncertainties that could cause actual results
to differ materially from those described in the forward-looking statements. Except as otherwise required by law, the Company undertakes
no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date
hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting the
Company is contained under the heading "Risk Factors" in the Company's annual report on Form 20-F for the fiscal year
ended December 31, 2022 filed with the U.S. Securities and Exchange Commission (the "SEC"), which is available on the SEC's
website, www.sec.gov
Public Relations Manager
Inspira Technologies
Copyright 2018-2024 Inspira Technologies OXY B.H.N. LTD., All